Compare Crispr Therapeutics AG (CRSP) vs Vital Farms Inc (VITL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs Vital Farms Inc — how do they compare? Crispr Therapeutics AG trades at $54.03 (market cap $5.23B), while Vital Farms Inc trades at $11.51 (market cap $496.50M). The key difference: Crispr Therapeutics AG is far larger — about 10.5× Vital Farms Inc's market cap, and Crispr Therapeutics AG is trading nearer its 52-week high, Vital Farms Inc nearer its low. Which is the better fit depends on your goals.
| CRSP | VITL | |
|---|---|---|
Market Cap | $5.23B | $496.50M |
Sector | Health | Consumer Staples |
52-Week High | $76.78 | $52.41 |
52-Week Low | $44.34 | $8.28 |
Enterprise Value | $3.65B | $583.51M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRISPR Therapeutics (CRSP) trades at $53.83, up 0.6% on the day, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a Q2 2026 EPS beat with a loss of $0.94 versus an expected $1.19 loss, driven by surging CASGEVY sales. However, financials show deep losses, with a net income margin of -4,101.26% in 2025 and negative operating cash flow, though financing activities provided liquidity.
The outlook is mixed: strong analyst consensus (57.9% buy ratings) and a $82.67 price target reflect optimism around CASGEVY growth and pipeline catalysts, but high valuation (P/S of 466.05) and persistent cash burn pose significant risks. Investment appeal hinges on successful clinical advancements and path to profitability.
VITL trades at $11.48, up 1.95% on the day, but faces significant technical headwinds with a bearish moving average signal. The company reported mixed Q2 2026 results, beating revenue estimates but posting a $0.47 per share loss amid industry oversupply challenges. Recent $125 million term loan financing provides liquidity support during this transitional period.
While analyst consensus remains positive with a $13.00 price target, near-term risks include margin compression from elevated costs and competitive pricing pressures. The stock's attractive P/S ratio of 0.67 offers value potential if the company can navigate current industry headwinds and return to profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About Vital Farms Inc
Vital Farms is a leading provider of ethically produced, pasture-raised eggs and butter in the United States. Operating as a Public Benefit Corporation, it manages a network of over 650 family farms to deliver high-welfare food products. It leverages a scalable 'asset-light' partnership model that prioritizes transparency and animal welfare to meet the growing consumer demand for clean-label and sustainable food sources.
Read more on VITL →
